

## AMENDMENT

Kindly amend the application as follows.

### In the Specification:

Please amend page 43, lines 8-10 to read as follows.

SEQ ID NO: 27      Lys-Leu-Val-Phe-Phe-Ala-Glu (all-D)

β<sup>1</sup> SEQ ID NO: 28      Lys-Leu-Val-Phe-Phe-Ala-Glu-NH<sub>2</sub> (all-D)

SEQ ID NO: 29      His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu (all-D)

Please amend page 44, lines 15-17 to read as follows.

The following are exemplary compounds derived from compound 20 (all-D

β<sup>2</sup> KLVFFA-NH<sub>2</sub>; SEQ ID NO: 20) by substituting one or two amino acid residue(s) with other amino acids.

### In the Claims:

~~Please~~ cancel claims 9-11 and 18-20, and amend claims 1-4, 6-8, and 12-17 to read as follows.

- β<sup>3</sup>
1. (Amended) A method for preventing or treating an amyloid-related disease in a subject, comprising: administering to the subject an antigenic amount of an all-D peptide, wherein said all-D peptide elicits the production of antibodies against said all-D peptide and induces an immune response by said subject, thereby preventing or reducing amyloid-induced neurodegeneration or amyloid fibril formation.